· Regulation · Regulatory Desk
A May 1 Federal Register notice (FR Doc. 2026-08552) signals the agency's intent to permanently close the 503B compounding pathway for the three highest-demand GLP-1 APIs. The desk also tracks the May 1 revision of Import Alert 66-80, which adds orforglipron and new product codes to GLP-1 import surveillance.
This brief is part of the Novusyn Research news desk. We track peptide clinical readouts, regulatory actions, and pharma developments in neutral, evidence-led language for scientifically literate readers.
For related context, see the full news desk, clinical trials tracker, regulation tracker, compound directory, and guides library.